G2G Bio

Beta

KRX Filings & Disclosures 2026

Management Discussion & Analysis

• • Revenue KRW 423M (-45.0% YoY), operating loss KRW 12.2B (-13.4%), net loss KRW 12.1B (-85.5%) for fiscal year 2025
• • Major revenue decline due to joint R&D schedule adjustment and CDO contract timing changes, expecting expansion from fiscal 2026

Risk Factors

• • FX exposure sensitivity KRW ±28.6M for 10% USD move in FY2025, down from KRW ±52.1M in FY2024
• • Financial liabilities due within 1 year KRW 3,400M in FY2025 vs KRW 108,679M in FY2024, reflecting large decrease in short-term debt

Business Overview

• • Revenue mix 2025: 64.8% from joint development/research services, 35.2% from licensing including GB-5001 for dementia
• • New second GMP plant construction scheduled for completion in 2027, with expected investment of KRW 80B for global GMP standards

What are the latest G2G Bio DART filings in 2026?

G2G Bio (KRX code 456160) has filed an annual report on March 18, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did G2G Bio file its most recent annual report?

G2G Bio filed its most recent annual report on March 18, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is G2G Bio's KRX stock code?

G2G Bio's KRX stock code is 456160. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 456160 to look up all G2G Bio disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does G2G Bio file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for G2G Bio.

Where can I find G2G Bio financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from G2G Bio annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.